B
Bullisch
Bullisch · 25%KMDA
$7.88
Szenariopreis
$7.770
+0.040 (+0.52%)Zum Schluss
Loading chart…
- Hoch
- 7.800
- Eröffnung
- 7.710
- Volumengewichteter Durchschnittskurs
- 7.75
- Volumen
- 88.20K
- Marktkap.
- 289.98M
- Tief
- 7.680
- Umsatz
- 683.57K
- EV/EBITDA, TTM
- 3.20
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
KI-Analyse of Kamada Ltd (KMDA)
KaufenKamada Ltd appears to be a good buy right now due to its recent FDA approval for a new laboratory, which enhances its operational capabilities and positions it well in the growing rabies immunoglobulin market. The current price of $7.77 is below the Fibonacci R1 level of $7.94, suggesting potential upside. Additionally, the company has shown a strong gross margin of 40.91% in Q2 2026, indicating solid profitability. However, a key risk is the recent Q1 earnings miss, where EPS was $0.07, falling short of expectations by $0.05, which could impact investor sentiment in the short term.
Analystenbewertungen (1)
+80.18% Aufwärtspotenzial
Kaufen
1 Kaufen
0 Halten
0 Verkaufen
Aktuell: 7.77
Tief
13.00
Durchschnitt
14.00
Hoch
15.00
H.C. Wainwright
Kaufen
$13
2025-12-09
H.C. Wainwright
2025-12-09
Kursziel
$13
Kaufen
Benchmark
Starker Kauf
$15
2025-03-21
Benchmark
2025-03-21
Kursziel
$15
Starker Kauf
HC Wainwright & Co.
Starker Kauf
$11
2025-03-06
HC Wainwright & Co.
2025-03-06
Kursziel
$11
Starker Kauf
HC Wainwright & Co.
Starker Kauf
$11
2025-01-10
HC Wainwright & Co.
2025-01-10
Kursziel
$11
Starker Kauf
HC Wainwright & Co.
Starker Kauf
$11
2024-11-14
HC Wainwright & Co.
2024-11-14
Kursziel
$11
Starker Kauf
Bewertungskennzahlen
Das aktuelle erwartete KGV von Kamada Ltd (KMDA) beträgt 16.53, verglichen mit dem 5-Jahres-Durchschnitt von 6.63.
Alphio-AI-Kursszenarien für KMDA
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die KMDA halten
Event-Zeitleiste
News
1.010-19NewsfilterKamada CEO to Attend Investor Conferences in November
7.509-17NASDAQ.COMKamada Addresses Surge in U.S. Rabies Demand
- 8.008-17Newsfilter
Kamada Declares $0.17 Cash Dividend Per Share
- 5.008-12Newsfilter
Kamada CFO Chaime Orlev to Depart for New Opportunities
- 9.508-12Newsfilter
Kamada Reports Record $100.2 Million Revenue in First Half of 2026
KMDA FAQ – beantwortet von Alphio AI
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Kamada Ltd appears to be a good buy right now due to its recent FDA approval for a new laboratory, which enhances its operational capabilities and positions it well in the growing rabies immunoglobulin market. The current price of $7.77 is below the Fibonacci R1 level of $7.94, suggesting potential upside. Additionally, the company has shown a strong gross margin of 40.91% in Q2 2026, indicating solid profitability. However, a key risk is the recent Q1 earnings miss, where EPS was $0.07, falling short of expectations by $0.05, which could impact investor sentiment in the short term.
1 analysts cover KMDA: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 14.00.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.